Fujifilm announced today that it entered into an asset purchase agreement for the global digital pathology business of Inspirata.
Upon completing the agreement, Fujifilm absorbs Inspirata’s Dynamyx digital pathology technology. Additionally, it takes on employees and customers of the company. Fujifilm expects to complete the transaction in early 2023. Terms of the agreement have not been disclosed.
Inspirata received FDA clearance for the Dynamyx digital pathology software in March. Dynamyx allows for the use of whole slide images (WSIs) for primary diagnosis in place of traditional glass slides. The software includes an intuitive user interface with many annotation tools. It also features a universal viewer and customizable third-party AI applications to be made available as needed by pathologists.
Fujifilm said in a news release that the acquisition expands its Synapse enterprise imaging offering. It enables the integration of pathology images in…